L’Oréal Groupe today announced that it has signed an agreement to acquire a majority stake in the British skincare brand Medik8. As part of the transaction, Inflexion, a leading European mid-market private equity firm, will remain a minority shareholder. The Founder will continue to serve on the board, with the current management committee also remaining in place to ensure continuity.
Founded by scientist Elliot Isaacs, Medik8 is best known for its iconic Crystal Retinal serum and its trademark CSA Philosophy©: Vitamin C and Sunscreen by Day, Vitamin A by night. Driven by scientific research and innovation, the brand offers ingredient-led premium skincare to deliver “results without compromise”. Still true to its professional origins, the brand has also evolved towards a diversified omni-channel sales mix across the most prominent online and offline retailers?in Europe, with a growing presence in the US.
This acquisition further strengthens L’Oréal’s Luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth.
“We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,” explained Cyril Chapuy, President of L’Oréal LUXE. “We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”
“This is an exciting day for Medik8,” said Simon Coble, CEO of Medik8. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”
L’Oréal will start consolidating Medik8 sales from the date of the closing of the transaction. As part of the agreement, L’Oréal has also secured rights to buyout in full the minority shareholders. The transaction is expected to be completed in the next few months after regulatory approvals and other customary conditions.
